Kamealya Farrell
Family · Sullivan, MONPI 1215462999
Payments from drug & device makers
Across 265 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$561
- AstraZeneca$400
- Lilly USA, LLC$326
- Boehringer Ingelheim$235
- Otsuka America Pharmaceutical, Inc.$185
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,636100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $1,357 |
| Novo Nordisk | 38 | $561 |
| AstraZeneca | 18 | $400 |
| Lilly USA, LLC | 18 | $326 |
| Boehringer Ingelheim | 13 | $235 |
| Otsuka America Pharmaceutical, Inc. | 9 | $185 |
| Gilead | 7 | $142 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $130 |
| Sanofi-aventis U.S. LLC | 4 | $120 |
| Amgen | 8 | $119 |
| Pfizer | 7 | $109 |
| Exact Sciences | 5 | $97 |
| GSK | 6 | $84 |
| Valinor Pharma, LLC | 4 | $64 |
| Merck | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Dexcom, Inc. | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $45 |
| Johnson & Johnson | 2 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $40 |
| Novartis | 2 | $37 |
| Amarin Pharma, Inc. | 2 | $32 |
| Abbott | 2 | $32 |
| Viatris Specialty LLC | 2 | $31 |
| Lundbeck LLC | 2 | $30 |
| Bayer | 2 | $29 |
| Halozyme Inc | 1 | $22 |
| Dynavax Technologies Corporation | 1 | $22 |
| Medtronic | 1 | $19 |
| Mylan Specialty L.p. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Vertex | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$4,636 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 30 | $36,161 |
| RybelsusSemaglutide | 11 | $22,698 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $14,157 |
| JardianceEmpagliflozin | 14 | $11,014 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $10,167 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $5,673 |
| Novolog FlexpenInsulin Aspart | 11 | $4,149 |
| Diclofenac Sodium | 35 | $2,107 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 66 | $1,506 |
| Gabapentin | 69 | $1,394 |
| Omeprazole | 98 | $1,196 |
| Hydroxyzine Hcl | 46 | $1,023 |
| Azelastine Hcl | 11 | $946 |
| Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide | 23 | $627 |
| Nystatin | 32 | $498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $561 | $58,85941 claims |
| Boehringer IngelheimCombivent Respimat, Jardiance | $235 | $25,17040 claims |
| GSKAnoro Ellipta | $84 | $10,16721 claims |
| AstraZenecaSymbicort | $400 | $5,67320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Sullivan
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.